Is option B+ the best choice?

Southern African Journal of HIV Medicine

Volumn 14, Issue 1, 2013, Pages 8-10

  Coutsoudis, A ^a   Goga, A ^b   Desmond, C ^c   Barron, P ^d   Black, V ^e   Coovadia, H ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; NEVIRAPINE;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; FERTILITY; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL ETHICS; PATIENT COMPLIANCE; PATIENT SAFETY; PREGNANT WOMAN; REVIEW; VIRUS TRANSMISSION;

EID: 84876562198     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.7196/SAJHIVMED.898     Document Type: Review

References (14)

1. World Health Organization HIV/AIDS Programme. Use of antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Executive Summary. Geneva: WHO, 2012. http://www.who.int/hiv/PMTCT-update.pdf (accessed 8 October 2012).
2. UNICEF. A Business case for Options B and B+ to eliminate mother to child transmission of HIV by 2015. A Discussion Document for the Global Steering Group Presented by the Business Leadership Council and UNICEF, in Collaboration with the Clinton Health Access Initiative. New York: UNICEF, 2012. http://eptctasiapacifc.org/content/business-case-options-b-and-b-eliminate- mother-child-transmission-hiv-2015-model-methodology (accessed 3 October 2012)
3. AIDS 2012. Washington DC. July, 2012. http://aids2012.org/WebContent/ File/AIDS2012-Plenary-Media- Release-25-July-2012-EN.pdf (accessed 8 October 2012)
4. Shapiro R, Hughes M, Oguwa A. Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana. N Engl J Med 2010;362(24):2282-2294. [http://dx.doi.org/10.1056/NEJMoa0907736]
5. Te Kesho Bora study group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): A randomised controlled trial. Lancet Infect Dis 2011;11(3):171-180. [http://dx.doi.org/10.1016/S1473-3099(10)70288-7]
6. Hargrove J, Humphrey J; ZVITAMBO Study Group. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010;24:F11-14. [http://dx.doi.org/10.1097/QAD.0b013e328335749d]
7. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505. [http://dx.doi.org/10.1056/NEJMoa1105243]
8. Chen JY, Ribaudo HJ, Souda S, et al. Highly Active Antiretroviral Terapy and Adverse Birth Outcomes Among HIV-Infected Women in Botswana. J Infect Dis 2012;206:1695-1705. [http://dx.doi.org/10.1093/infdis/jis553]
9. Struik GM, den Exter RA, Munthali C, et al. Te prevalence of renal impairment among adults with early HIV disease in Blantyre, Malawi. Int J STD AIDS 2011;22(8):457-462. [http://dx.doi.org/10.1258/ijsa.2011.010521]
10. Siberry G, Williams P, Mendez H, et al.; Pediatric HIV/AIDS Cohort study (PHACS). Safety of tenofovir use during pregnancy: Early growth outcomes in HIV-exposed uninfected infants. AIDS 2012;26(9):1151-1159. [http://dx.doi.org/ 10.1097/QAD.0b013e328352d135]
11. Rosen S, Fox M, Gill C. Patient retention in antiretroviral therapy prorams in Sub-Saharan Africa: A systematic review. PLoS Med 2007;4(10):1691-1701. [http://dx.doi.org/10.1371/journal.pmed.0040298] (Pubitemid 350035458)
12. Unge C, Södergård B, Marrone G. Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: A prospective cohort study. PLoS ONE 2010;5(10):1-12. [http://dx.doi.org/10.1371/journal.pone.0013613]
13. Nachega J, Uthman O, Anderson J, et.al. Adherence to antiretroviral therapy during and afer pregnancy in low-, middle-and high-income countries: A systematic review and meta-analysis. AIDS 2012;26(16):3039-3052. [http://dx.doi.org/101097/QAD0b013e328359590f]
14. Wagner B, Blower S. Universal Access to HIV Treatment versus Universal 'Test and Treat': Transmission, Drug Resistance & Treatment Costs. PLoS One 2012;7(9):e41212. [http://dx.doi.org/10.1371/journal.pone.0041212]